BridgeBio Pharma, Inc. Common Stock

BBIONASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
67.61 USD
↗ 0.28 (0.42%)AT CLOSE (11:59 AM EDT)
67.58
↘ 0.04 (0.05%)
POST MARKET (AS OF 06:55 PM EDT)
Post Market
AS OF 06:55 PM EDT
67.58
↘ 0.04 (0.05%)
🔴Market: CLOSED
Open?$67.45
High?$69.51
Low?$66.59
Prev. Close?$67.33
Volume?2.6M
Avg. Volume?3.3M
VWAP?$68.01
Rel. Volume?0.78x
Bid / Ask
Bid?$66.50 × 200
Ask?$68.50 × 100
Spread?$2.00
Midpoint?$67.50
Valuation & Ratios
Market Cap?13.2B
Shares Out?195.9M
Float?149.1M
Float %?76.2%
P/E Ratio?N/A
P/B Ratio?-5.79
EPS?-$3.68
Dividend?0.00%
Ex-Dividend?N/A

BridgeBio Pharma, Inc. Common Stock (BBIO) trades at $67.61 per share. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (31.7%) and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Themes
Biotech - Drug Development›Rare Disease TherapeuticsHealthcare - Genomics & Precision Medicine›Precision Medicine Platforms
Employees
839
Market Cap
12.8B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.bridgebio.com
Listed
2019-06-27
Address
3160 PORTER DR.
PALO ALTO, CA 94304
Phone: (650) 391-9740
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
90
Short Sent.?
45
Piotroski F-Score?3/9Weak
Altman Z-Score?-2.36Distress
Confidence?58%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?16.20%High
Short Interest?24.2M
Days to Cover?8.7
Free Float149.1M
Avg Daily Volume2.8M
Settlement Date2026-05-15
Financial Health
Current Ratio?1.52Adequate
Quick Ratio?1.48Adequate
Cash Ratio?1.08Strong
Debt/Equity?-1.09Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
S&P
97
-5.79CHEAP▾
P/S?
Peers
100
S&P
3
22.74HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-29.6CHEAP▾
EV/Sales?
Peers
100
S&P
3
25.49HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
80
31.7%STRONG▾
ROA?
S&P
3
-52.6%WEAK▾
Cash Flow & Enterprise
FCF?$-445120000
Enterprise Value?$14.8B
Fundamentals ratios updated end of day
MarketsMoversWatchlist